Full Report
Pfizer Inc.'s management explains the business in its own materials. The slides below do the most of that work, pulled from the documents preserved in Sources. Each source link opens the complete presentation at that slide in a new tab.
Fourth Quarter 2025 Earnings — Q4 / FY 2025
Management's fullest current statement of the whole company: FY2025 results, the 2026 strategy, the obesity bet and capital allocation. · Open the full document →
Oncology Innovation Day — 2024
The one deep-dive investor day in the corpus, on Pfizer's central growth engine — the post-Seagen oncology business, its platform, portfolio and 2030 ambition. · Open the full document →
More from management
First Quarter 2026 Earnings — Q1 2026 · 25 pages · The latest quarterly print — how the year is tracking against the 2026 guidance in the featured deck. · Open →
Investor Overview — 2026 J.P. Morgan Healthcare Conference — 2026 · 8 pages · An 8-page standalone overview of 2026 guidance, the margin plan and pipeline catalysts, if you want the short version. · Open →
Fourth Quarter 2024 Earnings — Q4 / FY 2024 · 24 pages · The FY2024 baseline these 2025 results are measured against. · Open →
Investor Overview — 2025 J.P. Morgan Healthcare Conference — 2025 · 11 pages · The prior-year J.P. Morgan overview, for comparison with the 2026 edition. · Open →
Pfizer Inc.'s management answers for the business every quarter. These are the exchanges that explain it best — verbatim, from the call transcripts preserved in Sources. Each link opens the full transcript at that page in a new tab.
Q1 2026 Earnings Call — Q1 2026
The current thesis in one call: how a patent settlement reset the post-2028 growth story, and why a clear beat still didn't lift guidance. · Open the full transcript →
The Vyndamax patent settlement is the quarter's real news: it pushes a $6bn+ LOE out ~2.5 years and restores a post-2028 growth claim.
Albert Bourla (Chairman and CEO): We also had two significant legal developments that improved our growth profile post-2028 and, of course, our cash flow outlook. Our recent settlement agreements resolving infringement of patents related to Vyndamax have the potential to change the growth profile of the company significantly post-2028. This gives us greater confidence that starting in 2029, we will enter a five-year period of high singledigit revenue CAGR.
p. 1 · Read in context →
The print and the offset engine: $14.5bn revenue, ~7% ex-COVID, and $3.1bn of launched/acquired products (+22%) meant to blunt the LOEs.
David Denton (CFO): In the first quarter of '26, revenues were $14.5 billion, exceeding our expectations and representing an operational increase of 2%. Excluding our COVID products, the underlying business delivered approximately 7% operational revenue growth […] Our launch and acquired products delivered $3.1 billion in the first quarter revenues and grew by approximately 22% operationally. […] We continue to invest behind these product groups to support their growth, which we expect will enable the company to partially offset upcoming LOE headwinds over the next several years.
p. 3 · Read in context →
Why a clear beat didn't lift the guide: Denton won't raise after Q1, citing COVID's back-half seasonality as the reason to hold.
Christopher Schott (JPMorgan); David Denton (CFO): I know you typically don't raise guidance with 1Q, but this seems like a very solid start to the year from a revenue perspective. […] As you well know, Chris, I have a philosophy of not adjusting guidance in Q1. If you look at our COVID franchise, it will always be back-half weighted because of the seasonality. So we have, if anything, de-risked delivery on that without raising guidance. So absent COVID seasonality, we might be raising guidance.
p. 6 · Read in context →
Q4 & Full-Year 2025 Earnings Call — Q4 2025
The clearest single view of the repositioning: the four priorities, the obesity bet, and how 2025's cash was allocated. · Open the full transcript →
The strategic frame for the cliff years: Seagen, Metsera and Biohaven as the offset, and obesity aimed at a ~$150bn market.
Albert Bourla (Chairman and CEO): 2026 is an important year in a pivotal investment period as we strive for industry-leading growth after several key products lose patent or regulatory exclusivity in the next few years. Seagen, Metsera, and Biohaven are the most significant strategic acquisitions in recent years. They have transformative potential for Pfizer Inc. […] The foundation of our strategy in obesity and adjacent conditions is targeting breakthrough medicines in what could be a $150 billion market.
p. 1 · Read in context →
FY2025 scorecard: $62.6bn revenue (-2% op, +6% ex-COVID) and $10.2bn of launched/acquired products growing 14% to backfill LOEs.
Dave Denton (CFO): For the full year 2025, we recorded revenues of $62.6 billion versus $63.6 billion last year, representing a 2% operational decline. Importantly, our operational revenue growth, when excluding contributions from our COVID-19 products, was 6%. […] Pfizer Inc.'s recently launched and acquired set of products delivered $10.2 billion in revenues for the full year of 2025 while growing approximately 14% operationally versus last year.
p. 4 · Read in context →
Where the cash went in 2025: $9.8bn dividend, $10.4bn internal R&D, $8.8bn of BD (mostly Metsera) — dividend first, buybacks later.
Dave Denton (CFO): In 2025, we returned $9.8 billion to shareholders via the quarterly dividend, invested $10.4 billion in internal R&D, and invested approximately $8.8 billion in business development transactions, primarily reflecting the Metsera acquisition and the 3S Bio licensing deal.
p. 6 · Read in context →
The obesity economics few discuss: ~40% of the $150bn market is ex-US, much of it cash-pay at $250-350, enabling faster launches.
Alexandre de Germay (President, International Developed Markets): What's really interesting in this category is actually the size of the market ex-US projected to be $150 billion, and 40% of that is actually ex-US. […] we see that there is high willingness to pay out of pocket across all mature markets, either in Europe or Australia or in Canada, and we see the price point being across $250 to $350, which is higher than what we had expected.
p. 7 · Read in context →
Q3 2023 Earnings Call — Q3 2023
The credibility test: management quantifies the COVID collapse and lays out the cost-cut-and-acquire response that defines today's Pfizer. · Open the full transcript →
The COVID unwind laid bare: the US returns 7.9m Paxlovid courses for $4.2bn of future revenue with no cash — the shock behind the reset.
Dave Denton (CFO): Before I review this quarter's results, I will address a couple of topics that have been top of mind with investors since our announcement on October 13. These topics relate to our future U.S. government Paxlovid revenue forecasts, as well as our multiyear cost realignment program. […] As a result of all of that, Pfizer has an obligation to deliver an estimated 8.9 million treatment courses for which we will record an approximately $4.2 billion of revenue beginning in 2024 as we deliver treatment courses. It is important to note that there is no cash compensation for the estimated 8.9 million treatment courses delivered.
p. 7 · Read in context →
Funding the pivot while cutting: $43bn committed to Seagen even as costs are slashed; buybacks wait until the balance sheet delevers.
Dave Denton (CFO): In the first nine months of 2023, we invested $7.9 billion in internal R&D, returned $6.9 billion to shareholders via our quarterly dividend, and allocated approximately $43 billion toward the proposed Seagen acquisition. […] And as we delever, we anticipate returning to a more balanced capital allocation strategy, inclusive of share repurchases.
p. 9 · Read in context →
Q4 2021 Earnings Call — Q4 2021
The peak call that set everything in motion: the $100bn COVID windfall and the plan to spend it on becoming a growth company. · Open the full transcript →
The peak, in management's words: a first-ever $100bn revenue midpoint for 2022 and a claim the COVID work changed the company for good.
Albert Bourla (Chairman and CEO): Our success in leading the fight against COVID-19 have not only made a positive difference in the world. I believe they have fundamentally changed our company and our culture forever. […] Our full year 2022 financial guidance, for example, includes, for the first time ever, a forecasted revenue midpoint, that it is triple-digit, $100 billion, and an adjusted diluted EPS midpoint of $6.45.
p. 4 · Read in context →
The playbook that defined the next five years: redeploy COVID cash into BD to stay a growth company, targeting +$25bn of 2030 revenue.
Albert Bourla (Chairman and CEO): Our goal is to continue to be a growth company from '25 to 2030, despite the impact of LOEs expected during that period. […] The strength of our balance sheet and cash flows allow us to pursue new business development opportunities going forward that could add at least $25 billion of risk-adjusted revenues to our 2030 top-line expectations.
p. 7 · Read in context →
The seeds, named early: Trillium, Biohaven (now Nurtec) and Arena (etrasimod) — deals that became today's growth portfolio.
Albert Bourla (Chairman and CEO): The acquisition of Trillium builds on our strong track record of leadership in oncology, enhancing our hematology portfolio […] Our strategic collaboration with Biohaven leverages our leading commercial capabilities in pain and women's health, with Biohaven's groundbreaking oral CGRP receptor antagonist […] And through our proposed acquisition of Arena, we plan to leverage Pfizer's leading research and global development capabilities to accelerate the clinical development of etrasimod
p. 10 · Read in context →
More calls
Q3 2025 Earnings Call — Q3 2025 · 12 pages · Where the Metsera obesity acquisition was won over Novo Nordisk's counterbid, and where the US MFN drug-pricing/tariff framework was settled with a grace period. · Open →
Q2 2025 Earnings Call — Q2 2025 · 16 pages · The tariff and Most-Favored-Nation pricing scare at its peak — the July 2025 policy letters and how management framed the Section 232 risk. · Open →
Q1 2025 Earnings Call — Q1 2025 · 5 pages · The obesity reset: the oral GLP-1 danuglipron was discontinued here, and the initial FY2025 guide was set before the Metsera pivot. · Open →
Q4 & Full-Year 2023 Earnings Call — Q4 2023 · 51 pages · The first full guidance of the reset era, with Seagen just closed — the reader gets the original 2024 rebuild framework. · Open →
Q1 2023 Earnings Call — Q1 2023 · 52 pages · The first earnings call after the $43bn Seagen announcement — how management first justified the oncology bet to analysts. · Open →
Q4 & Full-Year 2022 Earnings Call — Q4 2022 · 51 pages · The COVID-to-normal transition framing — 2023 set up as the year Pfizer pivoted from pandemic peak to base-business growth. · Open →
Pfizer Inc.'s annual reports contain management's most considered account of the business. These are the sections, passages and visual pages worth opening in the originals preserved in Sources.
Pfizer Inc. — FY2025 Annual Report (Form 10-K) — FY2025
The latest 10-K: how Pfizer is organized, the patent-cliff it must out-run, the 2025 results, and the landmark U.S. drug-pricing deal. · Open the full document →
Item 1. Business — p. 18 · Read the full section →
Defines what Pfizer is and how it is run — three operating segments, of which only Biopharma is reportable.
Commercial structure: three operating segments, Biopharma the only reportable one.
We manage our commercial operations through a global structure consisting of three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma, our innovative science-based biopharmaceutical business, is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. […] Biopharma is the only reportable segment.
p. 20 · Read in context →
Item 1. Business — Patents and Other Intellectual Property Rights — p. 25 · Read the full section →
The loss-of-exclusivity dynamic that governs pharma revenue, with management's own map of when key patents expire.
Management's warning of accelerating revenue loss from patent expiries, 2026–2030.
Once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price. […] We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years.
p. 29 · Read in context →
Item 1A. Risk Factors — p. 43 · Read the full section →
The company-specific risks that could genuinely bite: revenue concentration in a dozen products and payer/policy pricing pressure.
Concentration: 12 products were 65% of revenue in 2025; Eliquis alone 13%.
We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025. For example, Eliquis accounted for 13% of Total revenues in 2025.
p. 45 · Read in context →
Pricing pressure from consolidating payers and the Inflation Reduction Act.
As the U.S. third-party payor market consolidates further, and as the IRA prices become publicly available, we may face greater pricing pressure from third-party payors, including insurers and PBMs, as they continue to drive more of their patients to use lower cost alternatives or seek even larger rebates to control costs or offset losses from the IRA and other market pressures.
p. 43 · Read in context →
Item 7. Management's Discussion and Analysis — p. 70 · Read the full section →
Management's own account of 2025: revenue down 2%, plus the year's biggest strategic event — the U.S. government drug-pricing agreement.
Item 7. MD&A — Product Developments — p. 90 · Read the full section →
The pipeline replenishment that must offset the patent cliff — recent approvals and filings across the U.S., EU and Japan.
Note 17. Segment, Geographic and Other Revenue Information — p. 191 · Read the full section →
How Pfizer makes money: Biopharma segment economics, revenue ex-COVID (+6% underlying), and the geographic split.
More annual reports
Pfizer Inc. — FY2024 Annual Report (Form 10-K) — FY2024 · 213 pages · Prior year: the first full year absorbing the COVID-product decline and integrating the Seagen oncology acquisition. · Open →
Pfizer Inc. — FY2023 Annual Report (Form 10-K) — FY2023 · 218 pages · The transition year: COVID revenues collapse, large inventory write-offs, and the $43B Seagen deal close. · Open →
Pfizer Inc. — FY2022 Annual Report (Form 10-K) — FY2022 · 144 pages · Peak-COVID year — record revenue from Comirnaty and Paxlovid — the baseline the later declines are measured against. · Open →
Pfizer Inc. — FY2021 Annual Report (Form 10-K) — FY2021 · 166 pages · The Comirnaty launch year that doubled revenue — the start of the COVID-era earnings bulge. · Open →
Source: S&P Capital IQ consensus via Xpressfeed · Generated 2026-07-24.
Pfizer's consensus tape pairs a steadily declining forward with a long run of upside surprises. Analysts model revenue and normalized EPS falling every year through 2029 — EPS down roughly 22% from 2026 — even as the company has beaten normalized-EPS consensus in each of the last eight quarters. Those forward estimates have barely moved over six months, so the decline reads as settled Street math rather than a fresh downgrade; ratings skew to Hold, with price targets spanning $24 to $35.
Forward estimates
Currency: USD · Scale: money in millions, absolute · YoY uses the prior fiscal year from the feed; analyst count and range use the first displayed period.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | YoY | Analysts | Low / high |
|---|---|---|---|---|---|---|---|
| Revenue | $61.75bn | $59.37bn | $54.95bn | $54.53bn | -1.3% | 25 | $59.51bn / $63.12bn |
| EPS (normalized) | $2.94 | $2.83 | $2.42 | $2.28 | -8.6% | 25 | $2.80 / $3.12 |
Normalized EPS beat consensus all eight quarters, by 4% to 73% — but the surprise is shrinking
Current sequences by metric: Revenue: 4 consecutive beats; EPS (normalized): 8 consecutive beats.
Currency: USD · Scale: money in millions, absolute · Consensus is captured before each actual first became effective.
| Quarter | Metric | Consensus | Actual | Surprise | Outcome |
|---|---|---|---|---|---|
| Q1 FY2026 | Revenue | $13.80bn | $14.45bn | +4.7% | Beat |
| Q1 FY2026 | EPS (normalized) | $0.72 | $0.75 | +3.9% | Beat |
| Q4 FY2025 | Revenue | $16.83bn | $17.56bn | +4.3% | Beat |
| Q4 FY2025 | EPS (normalized) | $0.57 | $0.66 | +16.2% | Beat |
| Q3 FY2025 | Revenue | $16.52bn | $16.65bn | +0.8% | Beat |
| Q3 FY2025 | EPS (normalized) | $0.64 | $0.87 | +37.0% | Beat |
| Q2 FY2025 | Revenue | $13.53bn | $14.65bn | +8.3% | Beat |
| Q2 FY2025 | EPS (normalized) | $0.57 | $0.78 | +35.9% | Beat |
| Q1 FY2025 | Revenue | $14.05bn | $13.71bn | -2.4% | Miss |
| Q1 FY2025 | EPS (normalized) | $0.67 | $0.92 | +36.5% | Beat |
| Q4 FY2024 | Revenue | $17.26bn | $17.76bn | +2.9% | Beat |
| Q4 FY2024 | EPS (normalized) | $0.46 | $0.63 | +37.2% | Beat |
| Q3 FY2024 | Revenue | $14.87bn | $17.70bn | +19.1% | Beat |
| Q3 FY2024 | EPS (normalized) | $0.61 | $1.06 | +73.3% | Beat |
| Q2 FY2024 | Revenue | $13.02bn | $13.28bn | +2.0% | Beat |
| Q2 FY2024 | EPS (normalized) | $0.46 | $0.60 | +30.9% | Beat |
Estimate momentum
The largest six-month change is FY2028 revenue, down about 1%.
Currency: USD · Scale: money in millions, absolute · Point-in-time consensus; Δ90d is Now versus 90d.
| Metric | FY | 180d | 90d | 30d | Now | Δ90d |
|---|---|---|---|---|---|---|
| Revenue | FY2027 | $58.97bn | $58.69bn | $59.32bn | $59.37bn | +1.2% |
| Revenue | FY2028 | $55.53bn | $54.84bn | $55.36bn | $54.94bn | +0.2% |
| EPS (normalized) | FY2027 | $2.85 | $2.82 | $2.83 | $2.83 | +0.5% |
| EPS (normalized) | FY2028 | $2.44 | $2.40 | $2.41 | $2.42 | +0.9% |
Widest disagreement is on 2027 GAAP profit and 2028 profitability, not the top line
2027 GAAP net income spans $5.7bn–$13.6bn across 8 analysts; 2028 EBITDA and normalized EPS ranges are also wide, while revenue estimates cluster tightly.
Currency: USD · Scale: money in millions, absolute · Spread/mean is absolute high-low divided by absolute mean.
| Metric | Period | Mean | Low–high | Spread/mean | Analysts |
|---|---|---|---|---|---|
| Net income (GAAP) | FY2027E | $10.27bn | $5.72bn–$13.55bn | 76.2% | 8 |
| EBITDA | FY2028E | $20.54bn | $17.54bn–$24.99bn | 36.2% | 10 |
| EPS (normalized) | FY2028E | $2.42 | $2.07–$2.97 | 37.2% | 19 |
Ratings skew to Hold — 16 of 28 — with targets from $24 to $35
Ten Buy/Outperform ratings offset two bearish; the mean target is about $29 across 26 estimates.
Currency: USD · Scale: money in millions, absolute · Analyst counts shown explicitly.
| Street view | Reading | Analysts |
|---|---|---|
| Recommendation mix | Buy 8, Outperform 2, Hold 16, Underperform 1, Sell 1 | 28 |
| Consensus score | 2.46 | 28 |
| Target price | mean $28.75; median $28.00; high $35.46; low $24.00 | 26 |
Outer-year coverage thins sharply — treat 2029 as indicative
FY2029 EBITDA carries a single estimate and GAAP net income and EPS just three each; free cash flow and net debt are means only, with no ranges.
Visible Alpha broker models via S&P Xpressfeed · 20 brokers · 2076 line items · freshest revision 2026-07-20.
The Street models Pfizer's revenue essentially flat in FY-2026 (~$61.8B) before a mid-single-digit decline — roughly $59.5B in FY-2027 and $54.8B in FY-2028 — as Eliquis, Ibrance and other franchises lose exclusivity. An oncology ramp led by Padcev and a small-but-rising pipeline are the modeled offsets; the total-revenue consensus is tight even as brokers disagree sharply on the mix.
Loss-of-exclusivity is the story: Eliquis, Ibrance and Xtandi all roll off
| Line | FY-2025A | FY-2026E | FY-2027E | FY-2028E | YoY | Brokers |
|---|---|---|---|---|---|---|
| LOE cliff | — | — | — | — | — | — |
| Eliquis alliance revenue - IH | $7.99bn | $8.33bn | $7.09bn | $3.66bn | +4.3% | 20 |
| Ibrance | $4.10bn | $3.85bn | $2.90bn | $1.56bn | -6.0% | 20 |
| Xtandi | $2.21bn | $2.01bn | $1.31bn | $586.35m | -9.0% | 20 |
| Xeljanz | $1.04bn | $710.46m | $475.49m | $333.75m | -31.4% | 20 |
| COVID | — | — | — | — | — | — |
| Comirnaty | $4.01bn | $3.19bn | $2.98bn | $2.73bn | -20.5% | 20 |
| Paxlovid | $2.66bn | $1.26bn | $1.20bn | $1.13bn | -52.5% | 20 |
Padcev leads the offset; Nurtec and Abrysvo build while Vyndaqel plateaus
| Line | FY-2025A | FY-2026E | FY-2027E | FY-2028E | YoY | Brokers |
|---|---|---|---|---|---|---|
| Growth | — | — | — | — | — | — |
| Padcev | $1.98bn | $2.50bn | $2.95bn | $3.39bn | +26.5% | 20 |
| Nurtec ODT | $1.47bn | $1.71bn | $1.93bn | $2.13bn | +16.3% | 20 |
| Abrysvo | $769.80m | $1.03bn | $1.11bn | $1.23bn | +33.8% | 20 |
| Plateau | — | — | — | — | — | — |
| Vyndaqel | $6.41bn | $6.75bn | $6.57bn | $6.19bn | +5.3% | 20 |
The pipeline is the swing factor — near-zero today, ~$1.3B modeled by FY-2028
Modeled total pipeline revenue rises from essentially nothing in FY-2025 to a ~$1.3B median by FY-2028, but the range runs from $0 to ~$4.4B. It is the single least-settled line in the set and the swing factor for whether the top line stabilizes.
Where broker models disagree
| Line | Period | Median | Q1–Q3 | Min–max | Brokers |
|---|---|---|---|---|---|
| Total pipeline revenue | FY-2028E | $1.29bn | $885.30m–$2.33bn | $0.00–$4.41bn | 20 |
| Vyndaqel | FY-2028E | $6.07bn | $5.64bn–$6.71bn | $5.20bn–$7.54bn | 20 |
| Eliquis alliance revenue - IH | FY-2028E | $3.62bn | $3.34bn–$3.86bn | $2.30bn–$5.32bn | 20 |
| Ibrance | FY-2028E | $1.58bn | $1.30bn–$1.69bn | $871.27m–$2.55bn | 20 |
Coverage is deep and fresh on the base, but the pipeline lines thin out
Most product lines carry 18–20 brokers with revisions into July 2026, so the revenue base is well covered. The pipeline and new-product lines that determine the offset to the cliff fall to a handful of brokers — and near zero in FY-2025–26 — so those forecasts are thinner than the headline coverage implies.
Headline P&L consensus, momentum and beat/miss live in the CapIQ tab.
Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-05-05 · generated 2026-07-24.
Latest call digest
Pfizer Inc., Q1 2026 Earnings Call, May 05, 2026 · 2026-05-05T14:00:00
Q1 2026 call — May 5, 2026. Pfizer opened the year ahead of its own plan: revenues of $14.5 billion (+2% operationally, ~7% ex-COVID), reported EPS of $0.47 and adjusted EPS of $0.75, both above expectations. Management framed the quarter around two legal developments rather than the print itself — the Vyndamax (tafamidis) patent settlement pushing that LOE out roughly 2.5 years to mid-2031, and a Belgian court ruling on the EU Comirnaty contracts. Together these underpin a restated claim of a high single-digit five-year revenue CAGR beginning in 2029 and improved post-2028 cash flow. Prepared remarks leaned heavily on the oncology pipeline (Padcev EV-304 in muscle-invasive bladder cancer, Elrexfio MagnetisMM-5, atirmociclib), the newly closed Metsera obesity platform, a first-disclosed 35-serotype next-gen adult pneumococcal candidate, and AI across R&D and commercial.
The Q&A reality was more skeptical. Despite the beat, CFO Dave Denton declined to raise full-year guidance, invoking his standard practice of not adjusting after Q1 and the back-half weighting of COVID — conceding that 'absent that, we probably would be raising guidance.' Analysts pressed hardest on capital allocation: whether the Vyndamax clarity opens the door to larger M&A (and what that means for the dividend), when buybacks return, and how the pipeline bridges the stacked 2026-2028 LOEs. Management held the line that the dividend is preserved, that share repurchase moves 'back into greater consideration' but is not imminent, and that a transformative merger is 'not right now very high in our list.' Guidance was reaffirmed, not raised.
Participant coverage from the latest call.
| Group | Participants | Count |
|---|---|---|
| Management | Operator; Francesca DeMartino — Chief Investor Relations Officer, Pfizer Inc.; Albert Bourla — Chairman of the Board & CEO, Pfizer Inc.; David Denton — Executive VP & CFO, Pfizer Inc.; Chris Boshoff — Chief Scientific Officer and President of Research & Development, Pfizer Inc.; Alexandre de Germay — Executive VP & Chief International Commercial Officer, Pfizer Inc.; Aamir Malik — Executive VP & Chief U.S. Commercial Officer, Pfizer Inc. | 7 |
| Analysts | Vamil Divan — MD of Healthcare Research & Senior Equity Research Analyst, Guggenheim Securities, LLC, Research Division; David Risinger — Senior Research Analyst & Senior MD of Biopharma, Leerink Partners LLC, Research Division; Christopher Schott — Senior Analyst, JPMorgan Chase & Co, Research Division; Kerry Holford — Analyst, Joh. Berenberg, Gossler & Co. KG, Research Division; Umer Raffat — Senior MD & Senior Analyst of Equity Research, Evercore ISI Institutional Equities, Research Division; Asad Haider — MD & Senior Healthcare Strategist, Goldman Sachs Group, Inc., Research Division; Evan Seigerman — MD & Senior BioPharma Research Analyst, BMO Capital Markets Equity Research; Courtney Breen — Senior Research Analyst, Bernstein Institutional Services LLC, Research Division; Louise Chen — Research Analyst, Scotiabank Global Banking and Markets, Research Division | 9 |
Curated latest-call exchanges; one row per analyst topic.
| Analyst | Firm | Topic | What changed in Q&A |
|---|---|---|---|
| Chris Schott | JPMorgan | Guidance not raised; BD appetite | Asked why a strong start did not lift guidance and whether Vyndamax clarity enables larger deals; Denton cited COVID back-half seasonality and said absent that they would be raising, and kept BD framed around $7B capacity. |
| Umer Raffat | Evercore ISI | Dividend integrity vs transformative M&A | Probed the odds of a large, dividend-threatening deal and how Bourla and the Board view his tenure and dividend continuity; Bourla said a mega-merger is not a near-term priority given the AI-transformation focus. |
| Asad Haider | Goldman Sachs | Bridging the LOE gap to 2029 growth | Pressed on levers to hit high single-digit CAGR against stacked LOEs and base-business assumptions; Bourla leaned on risk-adjusted pipeline breadth and launched/acquired products growing 22%. |
| Evan Seigerman | BMO Capital Markets | Share repurchases | Asked what else is needed to start buying back stock at current levels; Denton said repurchases move back into greater consideration but the current priority remains R&D and BD investment. |
| Kerry Holford | Berenberg | Comirnaty ex-US and Belgian ruling | Asked about EU vaccination rates and the read-through of the April 2026 Belgian judgment; management said the Q1 Comirnaty decline reflected a lapsed UK contract, not vaccination trends, and work has begun with Poland and Romania to execute the ruling. |
| David Risinger | Leerink Partners | Oncology readouts and org restructuring | Asked about SV and mevrometostat pivotal readouts and the reorganization of BD and strategy; Bourla detailed moving BD under R&D and executive-team reductions, Boshoff framed the mid-year oncology readouts. |
| Vamil Divan | Guggenheim Securities | ADA obesity data expectations | Asked what Pfizer will present at ADA; Boshoff detailed VESPER-1/2/3 disclosures and said amylin monotherapy data comes in the second half. |
| Courtney Breen | Bernstein | Sigvotatug vedotin frontline positioning | Asked how the planned first-line all-comers SV study is positioned versus Symbiotic-Lung-01; Boshoff pointed to the PD-L1-high combination signal and mid-year second-line readout. |
Theme tracker
Themes are curator-classified across supplied calls.
| Theme | Status | Quarters mentioned | Read-through |
|---|---|---|---|
| COVID revenue decline and guidance derisking | persisted | Q2 2023, Q3 2023, Q4 2023, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | COVID has been the dominant swing factor across the entire window — from the 2023 credibility episode through repeated 'derisking' of back-half seasonality. By Q1 2026 it is a smaller, ex-COVID ~7% growth story, but management still cites COVID seasonality as the reason not to raise. |
| Cost realignment and productivity savings | persisted | Q3 2023, Q4 2023, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | The savings target has been steadily enlarged — $3.5B launched in Q3 2023, then $4B, $4.5B, and by 2025 an aggregate ~$7.2B net cost target plus a separate $1.5B manufacturing program. A consistent, on-track message every quarter. |
| LOE cliff (2026-2028) and post-2028 CAGR | persisted | Q4 2024, Q1 2025, Q3 2025, Q4 2025, Q1 2026 | The patent-cliff transition is the central strategic frame. The Q1 2026 Vyndamax settlement materially reshaped it, extending a $6B+ product and letting management restate a high single-digit five-year CAGR from 2029. |
| Obesity / metabolic strategy | emerged | Q1 2025, Q3 2025, Q4 2025, Q1 2026 | Moved from setback to centerpiece: danuglipron was discontinued in Q1 2025, then the ~$4.9B Metsera acquisition (announced Q3 2025, contested by Novo, closed by Q4 2025) made obesity a lead growth pillar, with VESPER data and a China GLP-1 launch by Q1 2026. |
| Oncology / Seagen ADC platform | persisted | Q2 2024, Q4 2025, Q1 2026 | Consistently positioned as the most advanced growth engine; roughly half of 2026 key readouts are oncology. Candor has crept in — management conceded on the Q4 2025 call that no ADC has beaten docetaxel in second-line lung, a readout still pending. |
| Capital allocation, BD discipline and the dividend | persisted | Q3 2024, Q4 2024, Q1 2025, Q4 2025, Q1 2026 | Sharpened by Starboard's involvement in late 2024, this recurs as questions on BD capacity (which swung from ~$13B to ~$7B post-Metsera), buyback timing and dividend safety. Management's answer is unchanged: dividend preserved, buybacks deferred, tuck-in-biased BD. |
| Trade, tariffs and MFN drug pricing | emerged | Q1 2025, Q2 2025, Q3 2025 | Policy risk dominated the 2025 calls — the Section 232 probe, the July 2025 Trump MFN letter, and a US-government agreement with a three-year tariff grace period reached in Q3 2025. It receded from the Q4 2025 and Q1 2026 discussions once a deal framework was in place. |
| AI across R&D, commercial and manufacturing | emerged | Q4 2025, Q1 2026 | A newer emphasis: Q4 2025 disclosed scaling to more than 1,200 GPUs, and Q1 2026 elevated AI to a headline strategic priority for compressing R&D timelines. |
Guidance ledger
Quotes, calls, and speakers are source-verified; outcomes are curator-classified.
| Verbatim guidance | Call | Speaker | Curator outcome | Outcome note |
|---|---|---|---|---|
| “We continue to expect total company revenues in the range of $59.5 billion to $62.5 billion, and adjusted diluted earnings per share in the range of $2.80 to $3 a share.” | Pfizer Inc., Q1 2026 Earnings Call, May 05, 2026 · 2026-05-05T14:00:00 | David Denton | pending | FY2026 guidance reaffirmed, not raised, despite a Q1 beat; full-year result not yet in the supplied call history. |
| “We expect total company full year '26 revenues to be in the range of $59.5 billion to $62.5 billion and full year '26 adjusted diluted earnings per share to be in the range of $2.80 to $3 a share” | Pfizer Inc., Q4 2025 Earnings Call, Feb 03, 2026 · 2026-02-03T15:00:00 | David Denton | pending | Initial FY2026 guide, set alongside a FY2025 result of $62.6B revenue and $3.22 adjusted EPS; 2026 outcome not yet in the supplied history. |
| “we are raising and narrowing our full year 2025 adjusted diluted earnings per share guidance by approximately $0.08 at the midpoint to $3 a share to $3.15 a share.” | Pfizer Inc., Q3 2025 Earnings Call, Nov 04, 2025 · 2025-11-04T15:00:00 | David Denton | kept | FY2025 adjusted EPS finished at $3.22 per the Q4 2025 call, above this raised range. |
| “our revised full year '25 adjusted diluted earnings per share range is now $2.90 to $3.10 a share.” | Pfizer Inc., Q2 2025 Earnings Call, Aug 05, 2025 · 2025-08-05T14:00:00 | David Denton | kept | FY2025 adjusted EPS of $3.22 exceeded this mid-year raised range. |
| “We expect total company full year 2025 revenues to be in the range of $61 billion to $64 billion and full year 2025 adjusted diluted earnings per share to be in the range of $2.80 to $3 a share” | Pfizer Inc., Q1 2025 Earnings Call, Apr 29, 2025 · 2025-04-29T14:00:00 | David Denton | kept | FY2025 landed at $62.6B revenue (within range) and $3.22 adjusted EPS (above the initial range). |
| “We now expect revenues in the range of $61 billion to $64 billion” | Pfizer Inc., Q3 2024 Earnings Call, Oct 29, 2024 · 2024-10-29T14:00:00 | David Denton | kept | Raised FY2024 revenue guide; the year closed at $63.6B, within the range. |
| “we expect adjusted diluted earnings per share of $2.45 to $2.65” | Pfizer Inc., Q2 2024 Earnings Call, Jul 30, 2024 · 2024-07-30T14:30:00 | David Denton | kept | Raised FY2024 adjusted EPS guide; the year finished at $3.11, well above after subsequent raises. |
Q&A pressure map
Question counts and firms are curator tallies; analyst coverage shown above.
| Topic | Questions | Firms | Pressure / response |
|---|---|---|---|
| COVID revenue trajectory and back-half derisking | 6 | Evercore ISI, Wells Fargo, Wolfe Research, Berenberg, TD Cowen | The most persistent line of questioning across the window. After the 2023 miss, analysts repeatedly tested how much COVID risk was baked into guidance; management's stock answer became that COVID is 'derisked' and seasonally back-half weighted. |
| Capital allocation, BD capacity and dividend safety | 5 | UBS, JPMorgan, Evercore ISI, BMO Capital Markets, Citi | Intensified by Starboard in late 2024 and again on the Q1 2026 call; analysts push on buyback timing, deal size and dividend durability, and management consistently defers buybacks while affirming the dividend. |
| Tariffs, MFN and drug-pricing policy | 5 | UBS, Cantor, TD Cowen, BofA, Jefferies | Dominated the 2025 calls. Analysts sought a quantified 2025-2026 policy impact; management repeatedly declined to size it, saying it was still under active discussion — a conservative non-answer rather than a clear evasion. |
| Obesity / Metsera program and data quality | 4 | JPMorgan, TD Cowen, Guggenheim, Leerink Partners | Skeptics questioned whether Metsera's data is differentiated versus incumbents and worth the contested acquisition; management defended diligence and monthly-dosing differentiation. |
| Oncology pipeline readouts (SV, ADC vs docetaxel) | 4 | Jefferies, Bernstein, Morgan Stanley, Leerink Partners | Analysts pressed on the second-line lung ADC bar; management conceded no ADC has yet beaten docetaxel there and pointed to a pending mid-year readout. |
Language shifts
Only language evidence verified against the referenced component is shown.
| Observation | Verbatim evidence | Call ID | Component |
|---|---|---|---|
| In 2024 management's register was defensive and credibility-focused after the COVID miss, repeatedly invoking caution. | “We know credibility is extremely important for us.” | 1875220311 | 52 |
| Dividend protection was cast in unusually emphatic terms during the post-miss period. | “The dividend is a sacred cow for us.” | 1875220311 | 57 |
| By late 2025 the tone toward competition turned combative, adopting aggressive new vocabulary around the Metsera contest. | “What they want is to catch and kill an emerging competitor” | 1961670320 | 11 |
| By Q1 2026 the language shifted to conviction about the post-cliff growth outlook, replacing hedged projections with 'clear line of sight.' | “Following the Vyndamax settlement, we now have a clear line of sight to a high single-digit 5-year revenue CAGR post-2028.” | 1991561932 | 3 |
The call history reframes Pfizer's debate from the 2023 COVID-credibility crisis to whether an enlarged pipeline and the Vyndamax reprieve can bridge the 2026-2028 patent cliff to renewed growth from 2029. Management has delivered on the beat-and-raise cadence it set for 2024-2025, which lends some weight to its post-2028 confidence, but the recurring, unresolved analyst pressure on buybacks, deal size and dividend durability signals the market is not yet taking that bridge for granted.
Competitors describe Pfizer Inc.'s market in their own filings and calls. These verified passages and visual pages show where their strategies meet, using source documents preserved in Sources.
Moderna, Inc. (MRNA)
Moderna is Pfizer's most direct, by-name rival: the two firms are the leading mRNA COVID-19 vaccine competitors (Spikevax vs. Comirnaty), now also collide in adult RSV vaccines, and are locked in cross-border mRNA patent litigation. Moderna's 10-K names Pfizer explicitly more than any other peer here.
Moderna names Pfizer/BioNTech as its principal COVID-19 vaccine rival and Pfizer as an RSV vaccine rival that reached the U.S. market first
We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. […] With respect to our RSV vaccine, we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date.
p. 57 · Read in context →
Moderna says it is shut out of many European COVID-vaccine markets by a competitor's European Commission contract running to end-2026
including against Pfizer and Sanofi for sales of our COVID vaccines and Pfizer and GSK for our RSV vaccine. […] we have been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026.
p. 75 · Read in context →
Moderna's summary of its multi-country patent-infringement campaign against Pfizer and BioNTech over its mRNA platform
We have brought patent-infringement actions against Pfizer Inc. (Pfizer), BioNTech SE (BioNTech) and related entities in the U.S. District Court for the District of Massachusetts, Germany, the Netherlands, the UK, Ireland and Belgium concerning our mRNA platform technology and disease-specific vaccine designs.
p. 217 · Read in context →
Merck & Co., Inc. (MRK)
Merck attacks Pfizer's single largest vaccine franchise — the Prevnar pneumococcal line — from both sides: a dedicated adult 21-valent vaccine (Capvaxive) and a pediatric/adult vaccine (Vaxneuvance). Merck's own filing quantifies Capvaxive's ramp and blames competition for Vaxneuvance's flat U.S. sales.
Merck describes Capvaxive, its adult-only 21-valent pneumococcal vaccine launched in 2024 that competes with Pfizer's Prevnar (2025 sales ~$759M)
Sales of Capvaxive, a vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by certain serotypes in individuals 18 years of age and older
p. 84 · Read in context →
Merck attributes flat U.S. sales of its pneumococcal vaccine Vaxneuvance partly to competition — the same pediatric/adult market Pfizer's Prevnar leads
U.S. sales of Vaxneuvance were nearly flat year over year as a benefit from public and private sector purchasing patterns in the U.S. was offset by lower demand due to competition.
p. 84 · Read in context →
GSK plc (GSK)
GSK is Pfizer's sharpest adult-vaccines rival: its Arexvy competes head-to-head with Pfizer's Abrysvo in adult RSV, and its Shingrix anchors the adult-immunization market Pfizer is trying to grow into. GSK also earns royalties on Pfizer's Abrysvo and Comirnaty.
GSK says its adult RSV vaccine Arexvy held market-leading U.S. share among older adults — the market Pfizer's Abrysvo also contests (Q3 FY2025 call)
Luke Miels, Chief Commercial Officer: Turning to Arexvy […] in the U.S., we maintained our market-leading share in the older adults population.
p. 8 · Read in context →
GSK notes royalty income tied to Pfizer's Abrysvo (RSV) and Comirnaty (COVID) vaccines (Q1 FY2026 call)
Royalties benefited from Abrysvo and Comirnaty income streams.
p. 8 · Read in context →
GSK reports a record quarter for its Shingrix shingles vaccine, sizing the scaled adult-vaccine franchise Pfizer competes against (Q1 FY2026 call)
Shingrix was a key driver in Q1, setting a record for quarterly sales, delivering more than GBP 1 billion, up 20%.
p. 2 · Read in context →
AstraZeneca PLC (AZN)
AstraZeneca is Pfizer's largest-cap oncology rival, overlapping in breast cancer (Truqap vs. Pfizer's Ibrance) and in the PARP/prostate/ovarian space (Lynparza vs. Pfizer's Talzenna). AZN's oncology franchise is larger and faster-growing, and its filing claims share gains in exactly those tumor types.
AstraZeneca cites rapidly reached peak share for Truqap in second-line metastatic breast cancer — a market anchored by Pfizer's Ibrance
Truqap sales in the US increased by 44% […] as a result of a rapidly reached peak share in second line biomarker-altered metastatic breast cancer
p. 27 · Read in context →
AstraZeneca reports U.S. share gains for its PARP inhibitor Lynparza across ovarian, breast and prostate cancers — the same indications Pfizer's Talzenna targets
Lynparza sales in the US increased by 8% […] as a result of share gains across ovarian, breast and prostate indications.
p. 27 · Read in context →
Johnson & Johnson (JNJ)
J&J's Innovative Medicine segment competes with Pfizer in oncology and immunology. Its multiple-myeloma franchise (led by DARZALEX) is the incumbent wall Pfizer's Elrexfio must displace, while its immunology book (STELARA, TREMFYA) sits in the same market as Pfizer's Cibinqo, Litfulo and Velsipity.
J&J's DARZALEX is its single largest product at ~15% of revenue — the entrenched multiple-myeloma incumbent Pfizer's Elrexfio competes against
Sales of the Company's largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 15.0% of the Company's total revenues for fiscal 2025.
p. 11 · Read in context →
J&J's immunology sales fell as STELARA lost ground to biosimilars while TREMFYA gained share — the psoriasis/IBD market where Pfizer's I&I drugs compete
Immunology products sales were […] a decline of 11.8% as compared to the prior year primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Medicare Part D redesign. The growth of TREMFYA (guselkumab) was due to share gains and market growth.
p. 34 · Read in context →
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb competes with Pfizer in immuno-oncology (Opdivo) and in oral immunology (Sotyktu vs. Pfizer's Litfulo and Cibinqo), even as the two firms co-market Eliquis as alliance partners. BMS's own filing describes the crowded IO market Pfizer's oncology portfolio also plays in.
Bristol Myers Squibb on the crowded immuno-oncology market where its lead PD-1 drug Opdivo competes in lung cancer and melanoma
Our IO products, particularly Opdivo, operate in a highly competitive marketplace. In addition to competing for market share with other IO products in approved indications such as lung cancer and melanoma, we face increased competition from existing competing IO products that receive FDA approval for additional indications and for new IO agents that receive FDA approval and enter the market.
p. 26 · Read in context →
Bristol Myers Squibb's oral psoriasis drug Sotyktu, a TYK2 inhibitor competing in the same market as Pfizer's Litfulo and Cibinqo
Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
p. 9 · Read in context →
More peer documents
MRNA_annual_report_FY2024 — 249 pages · Prior-year Moderna 10-K carrying the same Pfizer COVID/RSV competition framing and an earlier snapshot of the mRNA patent litigation — useful for the two-year trend. · Open →
Q4_FY2025 — 12 pages · Moderna management's full-year call: commentary on COVID vaccine share losses and RSV market entry against Pfizer. · Open →
MRK_annual_report_FY2024 — 192 pages · Merck's prior 10-K covering Capvaxive's launch year and Vaxneuvance framing before the 2025 competitive pressure — baseline for the Prevnar share fight. · Open →
JNJ_annual_report_FY2024 — 131 pages · Prior-year J&J oncology and immunology segment sizing to trend DARZALEX, STELARA and TREMFYA against Pfizer-overlapping franchises. · Open →
AZN_annual_report_FY2024 — 132 pages · AstraZeneca's FY2024 report, including its rare-disease assets acquired from Pfizer and the earlier oncology growth trajectory. · Open →
Q4_FY2025 — 15 pages · Bristol Myers Squibb's full-year call with management commentary on Opdivo/immuno-oncology competition and new-product launches. · Open →